Terms: = Ovarian cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
80 results:
1. Development and validation of age-specific risk prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer: a report from the Childhood cancer Survivor Study and St Jude Lifetime Cohort.
Im C; Lu Z; Mostoufi-Moab S; Delaney A; Yu L; Baedke JL; Han Y; Sapkota Y; Yasui Y; Chow EJ; Howell RM; Bhatia S; Hudson MM; Ness KK; Armstrong GT; Nathan PC; Yuan Y
Lancet Oncol; 2023 Dec; 24(12):1434-1442. PubMed ID: 37972608
[TBL] [Abstract] [Full Text] [Related]
2. Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for ovarian cancer.
Leman R; Muller E; Legros A; Goardon N; Chentli I; Atkinson A; Tranchant A; Castera L; Krieger S; Ricou A; Boulouard F; Joly F; Boucly R; Dumont A; Basset N; Coulet F; Chevalier LM; Rouleau E; Leitner K; González-Martin A; Gargiulo P; Lück HJ; Genestie C; ; Ray-Coquard I; Pujade-Lauraine E; Vaur D
Clin Cancer Res; 2023 Nov; 29(21):4419-4429. PubMed ID: 37756555
[TBL] [Abstract] [Full Text] [Related]
3. A quality improvement project to optimize access to psychosocial care for cancer survivors who experience fear of recurrence.
Pereira L; Nguyen P; Benea A; Townsley C
J Psychosoc Oncol; 2023; 41(6):721-731. PubMed ID: 37702764
[TBL] [Abstract] [Full Text] [Related]
4. Clinical parameters affecting survival outcomes in patients with low-grade serous ovarian carcinoma: an international multicentre analysis.
May T; Bernardini M; Lheureux S; Aben KKH; Bandera EV; Beckmann MW; Benitez J; Berchuck A; Bjørge L; Carney ME; Cramer DW; deFazio A; Dörk T; Eccles DM; Friedlander M; García MJ; Goode EL; Hein A; Høgdall CK; Jensen A; Johnatty S; Kennedy CJ; Kiemeney LA; Kjær SK; Kupryjańczyk J; Matsuo K; McGuire V; Modugno F; Paddock LE; Pejovic T; Phelan CM; Riggan MJ; Rodriguez-Antona C; Rothstein JH; Sieh W; Song H; Terry KL; van Altena AM; Vanderstichele A; Vergote I; Thomsen LCV; Webb PM; Wentzensen N; Wilkens LR; Ziogas A; Jiang H; Tone A;
Can J Surg; 2023; 66(3):E310-E320. PubMed ID: 37369443
[TBL] [Abstract] [Full Text] [Related]
5. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial.
Senkus E; Delaloge S; Domchek SM; Conte P; Im SA; Xu B; Armstrong A; Masuda N; Fielding A; Robson M; Tung N
Int J Cancer; 2023 Aug; 153(4):803-814. PubMed ID: 36971103
[TBL] [Abstract] [Full Text] [Related]
6. [The expression and significance of protease activated receptor 2 in ovarian epithelial carcinoma].
Liu SH; Ma YM; Zhang YN; Zhao XH; Wang HY; Li B
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):64-73. PubMed ID: 36709122
[No Abstract] [Full Text] [Related]
7. Premature ovarian insufficiency in female adolescent and young adult survivors of non-gynecological cancers: a population-based cohort study.
Flatt SB; Baillargeon A; McClintock C; Pudwell J; Velez MP
Reprod Health; 2023 Jan; 20(1):4. PubMed ID: 36593491
[TBL] [Abstract] [Full Text] [Related]
8. Other Primary Malignancies in Patients with Breast cancer Who Undergo Germline Panel Testing.
Murphy BL; Yi M; Gutierrez Barrera AM; Tripathy D; Hunt KK; Arun BK
Ann Surg Oncol; 2023 Mar; 30(3):1663-1668. PubMed ID: 36094691
[TBL] [Abstract] [Full Text] [Related]
9. Race, Affordability and Utilization of Supportive Care in ovarian cancer Patients.
Anyanwu MC; Ohamadike O; Wilson LE; Meernik C; Huang B; Pisu M; Liang M; Previs RA; Joshi A; Ward KC; Tucker T; Schymura MJ; Berchuck A; Akinyemiju T
J Pain Symptom Manage; 2022 Dec; 64(6):537-545. PubMed ID: 36058401
[TBL] [Abstract] [Full Text] [Related]
10. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract] [Full Text] [Related]
11. [IL-1β inhibitor sensitizes to olaparib in homologous recombination deficiency proficient ovarian cancer cells].
Xu JF; Cen YX; Tang SS; Ren Y; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2022 Jul; 57(7):519-529. PubMed ID: 35902786
[No Abstract] [Full Text] [Related]
12. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract] [Full Text] [Related]
13. Maintenance Therapy with Aromatase Inhibitor in epithelial ovarian cancer (MATAO): study protocol of a randomized double-blinded placebo-controlled multi-center phase III Trial.
McLaughlin PMJ; Klar M; Zwimpfer TA; Dutilh G; Vetter M; Marth C; du Bois A; Schade-Brittinger C; Reuss A; Bommer C; Kurzeder C; Heinzelmann-Schwarz V
BMC Cancer; 2022 May; 22(1):508. PubMed ID: 35524184
[TBL] [Abstract] [Full Text] [Related]
14. Is adjuvant chemotherapy necessary for young women with early-stage epithelial ovarian cancer who have undergone fertility-sparing surgery?: a multicenter retrospective analysis.
Ikeda Y; Yoshihara M; Yoshikawa N; Yokoi A; Tamauchi S; Nishino K; Niimi K; Kajiyama H
BMC Womens Health; 2022 Mar; 22(1):80. PubMed ID: 35313889
[TBL] [Abstract] [Full Text] [Related]
15. Dysregulated expression and functions of microRNA-330 in cancers: A potential therapeutic target.
Jafarzadeh A; Paknahad MH; Nemati M; Jafarzadeh S; Mahjoubin-Tehran M; Rajabi A; Shojaie L; Mirzaei H
Biomed Pharmacother; 2022 Feb; 146():112600. PubMed ID: 34968919
[TBL] [Abstract] [Full Text] [Related]
16. Effects of Gonadotropin-Releasing Hormone Analogs on ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast cancer in China: A Randomized Clinical Trial.
Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
[TBL] [Abstract] [Full Text] [Related]
17. Impact of Surgeon Type and Rurality on treatment and Survival of ovarian cancer Patients.
Weeks KS; Lynch CF; West MM; Carnahan RM; O'Rorke MA; Oleson JJ; McDonald ME; Charlton ME
Am J Clin Oncol; 2021 Oct; 44(10):544-551. PubMed ID: 34342289
[TBL] [Abstract] [Full Text] [Related]
18. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
Thein KZ; Piha-Paul SA; Tsimberidou A; Karp DD; Janku F; Zarifa A; Shah J; Milton DR; Bean S; McQuinn L; Gong J; Colen R; Carter BW; Subbiah V; Ogbonna DC; Pant S; Meric-Bernstam F; Naing A
Invest New Drugs; 2021 Oct; 39(5):1357-1365. PubMed ID: 33909232
[TBL] [Abstract] [Full Text] [Related]
19. Olaparib dose re-escalation in ovarian cancer patients who experienced severe and/or uncommon adverse events: A case series.
Ngu SF; Tse KY; Chu MMY; Ngan HYS; Chan KKL
Asia Pac J Clin Oncol; 2021 Apr; 17 Suppl 3():3-11. PubMed ID: 33860646
[TBL] [Abstract] [Full Text] [Related]
20. MicroRNA miR-330-3p suppresses the progression of ovarian cancer by targeting RIPK4.
Cai L; Ye L; Hu X; He W; Zhuang D; Guo Q; Shu K; Jie Y
Bioengineered; 2021 Dec; 12(1):440-449. PubMed ID: 33487072
[TBL] [Abstract] [Full Text] [Related]
[Next]
